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Chapter 1
The Role of Sleep in Memory Consolidation with an Induced Sleep-like state in Drosophila

1

Preface
I changed lab one year ago. The following chapter summarizes a portion of works I did in that
lab. However, I now have only limited access to those data. As a result, the first chapter of this
thesis is necessarily incomplete in its description of the data and analysis. More details can be
found in my co-authored publications.
1. Foraging alters resilience/vulnerability to sleep disruption and starvation in Drosophila.
Donlea J, Leahy A, Thimgan MS, Suzuki Y, Hughson BN, Sokolowski MB, Shaw PJ.
Proc Natl Acad Sci USA. 2012 Feb 14;109(7):2613-8. Doi:10.1073/pnas.1112623109.
Epub 2012 Jan30. PMID:22308351
2. Inducing sleep by remote control facilitates memory consolidation in Drosophila.
Donlea JM, Thimgan MS, Suzuki Y, Gottschalk L, Shaw PJ. Science. 2011 Jun
24;332(6073) ):1571-6. doi: 10.1126/science.1202249. PMID:21700877
3. Notch signaling modulates sleep homeostasis and learning after sleep deprivation in
Drosophila.
Seugnet L, Suzuki Y, Merlin G, Gottschalk L, Duntley SP, Shaw PJ. Curr Biol. 2011
May 24;21(10):835-40. doi: 10.1016/j.cub.2011.04.001. Epub 2011 May 5.
PMID:21549599
4. Sleep deprivation during early-adult development results in long-lasting learning deficits
in adult Drosophila.
Seugnet L, Suzuki Y, Donlea JM, Gottschalk L, Shaw PJ. Sleep. 2011 Feb 1;34(2):13746. PMID: 21286249
5. The perilipin homologue, lipid storage droplet 2, regulates sleep homeostasis and
prevents learning impairment following sleep loss.
Thimgan MS, Suzuki Y, Seugnet L, Gottschalk L, Shaw PJ. PLoS Biol. 2010 Aug
31;8(8). doi:pii: e1000466. 10.1371/journal.pbio.1000466. PMID: 20824166
6. Persistent short-term memory defects following sleep deprivation in a drosophila model
of Parkinson disease.
Seugnet L, Galvin JE, Suzuki Y, Gottschalk L, Shaw PJ. Sleep. 2009 Aug;32(8):984-92.
PMID: 19725249
7. Identifying sleep regulatory genes using a Drosophila model of insomnia.
Seugnet L, Suzuki Y, Thimgan M, Donlea J, Gimbel SI, Gottschalk L, Duntley SP, Shaw
PJ. J Neurosci. 2009 Jun 3;29(22):7148-57. doi: 10.1523/JNEUROSCI.5629-08.2009.
PMID: 19494137

2

8. Aversive phototaxic suppression: evaluation of a short-term memory assay in Drosophila
melanogaster.
Seugnet L, Suzuki Y, Stidd R, Shaw PJ. Genes Brain Behav. 2009 Jun;8(4):377-89. doi:
10.1111/j.1601-183X.2009.00483.x. Epub 2009 Feb 11. PMID:19220479
9. D1 receptor activation in the mushroom bodies rescues sleep-loss-induced learning
impairments in Drosophila.
Seugnet L, Suzuki Y, Vine L, Gottschalk L, Shaw PJ. Curr Biol. 2008 Aug
5;18(15):1110-7. doi: 10.1016/j.cub.2008.07.028. PMID:18674913
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Abstract
Introduction: Sleep plays an important role in memory consolidation. However, the underlying
mechanism remains elusive. The importance of sleep in the memory consolidation process has
been demonstrated by sleep deprivation studies in which sleep loss corresponded to poor
performance on memory tasks. A sleep induction approach, that allows us to study sleepmediated changes in the presence of sleep, provides further understanding of sleep’s role in the
memory consolidation process.
Method: We first developed a pharmacological method to induce a sleep-like state and
examined if the induced sleep-like state modulates memory consolidation in flies. Using sleep
induction, we then evaluated if changes in duration and timing of the induced sleep cause the
changes in memory outcomes to further understand the role of sleep in the memory consolidation
process.
Results: Gaboxadol, an extra-synaptic GABAA receptor agonist, induced a sleep-like state that
meets all the behavioral criteria of a spontaneous sleep-like state in flies. The induced sleep-like
state following Gaboxadol treatment facilitated the formation of long-term memory in Wild-type
flies. Inducing a sleep-like state in different strains of flies (ex. a series of memory mutants) and
under various experimental conditions (ex. following sleep deprivation) revealed the beneficial
role of induced sleep in memory processes, as supported by the observations that an increased
sleep-like state rescued memory deficits in memory mutants and may compensate memory
impairment caused by sleep-deprivation. By altering the duration and timing of sleep induction
following the training protocol that is only able to induce a short-term memory by itself, we
observed that a short-term memory was consolidated into a long-term memory even at when a
sleep-like state was induced for a short period of time (<4hrs) or induced at later time (>24hrs)
following the training.
Discussion: Incorporating Gaboxadol into food is a novel method to increase a sleep-like state
that was behaviorally and functionally equivalent to a spontaneous sleep-like state in flies. The
ability of an induced sleep to sustain the formation of long-term memory following interference
periods supports the active role of sleep in the memory consolidation process. Future studies
using sleep induction could complement studies from sleep deprivation and contribute to
identifying genes and neuronal circuits that link sleep with memory.

4

Introduction
Sleep plays an important role in memory consolidation (Payne et al., 2009; Saletin et al.,
2011; Stickgold and Walker, 2007; Walker, 2008; Walker et al 2005; Yoo et al., 2007). The link
between sleep and memory is adjoined by the observation that sleep disruption results in poor
performance of memory tasks (Graves et al., 2003; Guan et al., 2004). In addition, recent studies
have also suggested that sleep is implicated in several neurodegenerative disorders (Brown,
2002; Hayflick et al., 2013; Iranzo, 2013; Ju et al., 2014; Ju et al., 2013; Lehmann et al., 2013;
Malow, 2004; Sixel-Doring et al., 2014). However, how sleep affects the memory consolidation
process remains unclear. Additional experimental approaches, such as sleep induction, could aid
in a better understanding of the molecular mechanism that underlies how sleep affects memory
consolidation.
We used the fruit fly Drosophila melanogaster as a model to study the role of sleep in
memory for a few simple reasons. Its small size, rapid reproduction rates, approximate 15000
gene number and short life cycle make studies efficient and easily replicated. Its well
characterized biology and genetic tools such as the GAL4-UAS system allow easy manipulation
of gene expression in multiple ways (Hendricks et al., 2000). Moreover, although flies are
relatively simpler organisms when compared to mammals, the neural circuits that control
complex biological processes such as sleep and memory are well developed. Flies exhibit a
sleep-like state (Hendricks et al., 2000a; Hendricks et al., 2000b; Nitz et al., 2002; Shaw et al.,
2000) and are able to form memory (Blum et al., 2009; Tully et al., 1994; van Swinderen, 2009).
A sleep-like state in flies is also directly correlated with performance in memory task, as sleep
loss in flies corresponds to poor performance (Seugnet et al., 2009a; Seugnet et al., 2011a;
Seugnet et al., 2011b; Seugnet et al., 2009b; Seugnet et al., 2009c; Seugnet et al., 2008). Since
5

the ability of flies to recapitulate the effect of sleep on memory and many aspects of sleep appear
to be controlled genetically, fly does present an useful model for identification of the genes and
neuronal circuits that link sleep and memory.
Previously, taking advantage of fly genetics, we developed a method to induce a sleeplike state in flies (Donlea et al., 2011). This sleep-induction approach allowed us to determine
changes in memory in the presence of sleep, apart from the sleep-deprivation approach in which
the function of sleep is proposed based on the negative consequences of losing sleep.
Beneficially, correlating findings from both the sleep-induction and sleep-deprivation approaches
could help in the process to determine the function of sleep; the sleep induction approach
provides additional experimental strategies that would otherwise be difficult with the sleepdeprivation approach. While the use of genetics to stimulate a group of neurons in the fly’s brain
is one way to induce a sleep-like state, developing an additional approach which is independent
of genetics could open the door to a wide range of applications.
In fact, sleep-inducing drugs have been developed to increase amount of sleep for treating
sleep abnormalities and disturbances. Although these drugs increase inactive states, whether
medication-induced inactive states resemble to the spontaneous occurring sleep remains a
question. Since the levels of endogenous melatonin correlates with sleep-wake cycle, the
regulatory effect of increased melatonin level on sleep was studied. Although melatonin
treatment decreased time for falling sleep, melatonin treatment had no effect on maintaining
sleep (van den Heuvel et al., 2005). In contrast, Gaboxadol, an agonist for the δ-subunit of
extrasynaptic GABAA receptors, increases slow wave sleep and to maintain sleep in rats and
human (Dijk et al., 2012; Lancel, 1997; Lundahl et al., 2012; Lundahl et al., 2007).

6

Since the ability of Gaboxadol to increase a sleep-like state in flies remains unknown, in
the first part of this study, we tested if Gaboxadol induces quiescence in flies and characterized if
the increased quiescence following treatment had the same properties as spontaneous sleep.
In the second part of this study, we evaluated the effect of additional sleep-like states on
memory consolidation in flies. Since the sleep induction method allows temporal control of
induced sleep, we determined if modification in the duration and timing of additional sleep-like
states are associated with changes in memory.
In sum, results from this study provide a new method using drugs to induce a sleep-like
state in flies. Together with the previously demonstrated genetic method, the pharmacological
method could validate sleep induction as a method effectively to study the function of sleep. In
addition, the results from this study have also contributed to a better understanding of the effect
of additional sleep on memory consolidation. Future studies in sleep induction could
complement studies from sleep deprivation and contribute to identifying genes and neuronal
circuits that link sleep with memory.

7

Materials and Methods
Flies
Flies were maintained on a diet (yeast, dark corn syrup and agar) at 25°C with approximately 5060% humidity under light (8am-8pm): dark (8pm-8am) cycle. Flies used in this study: Canton-S
(CS) flies were used as Wild-type flies throughout this study, 104y-GAL4, 30y-GAL4, c929GAL4, UAS-NachBac, UAS-Lcch3-RNAi, UAS-GRD-RNAi, UAS-RDL-RNAi, UASGABABR1-RNAi, UAS-GABABR2-RNAi, UAS-GABABR3-RNAi, Blistered
(w*;P{GAL4}bs1348), Period ( per01). Flies used in experiment 1.4 (figure 9): rut2080>104y/+,
rut2080>UAS-NachBac, rut2080;104y-GAL4>UAS-NachBac, dnc1>104y/+, dnc1>UASNachBac, dnc1;104y>UAS-NachBac; dnc1 line was kindly provided by Dr. Bruno Van
Swinderen.
Memory mutant flies listed were ordered from Bloomington Fly Center. Dunce (dnc1), Latheo
(al[1]b[1]lat[6]c[1]sp[1]/SM5), Leonardo (P{ry[+t7.2]=IArB}14-3-3 zeta[P1188]/CyO;ry[506]),
Lio2 (w[1118];Df(2R)lio[2],pigeon[2]drl[2]), volado (scb[Vol-2]/CyO)

Pharmacology
Both Gaboxadol (sigma-aldrich CAS#85118-33-8) and SKF97541 were incorporated into fly
diet (yeast, dark corn syrup and agar) to reach final concentrations of 0.1mg/mL or 0.5mg/mL for
Gaboxadol and 40μM for SKF. Gaboxadol targets GABAA receptors whereas SKF targets
GABAB receptors.
Hydroxyurea (HU) was used to chemically ablate mushroom bodies in fly larvae. Briefly, flies
were allowed to lay eggs on the freshly prepared apple juice plates. Hatched larvae was picked
and transferred to either the starvation plate (10% agar in dH2O) with yeast paste with HU (HU
8

group) or the starvation plate with yeast paste only (Vehicle control group) for 4 hours. After 4
hours of the treatment, larvae were transferred to a vial containing normal food (yeast, dark corn
syrup and agar).

Measurement of sleep-like state in flies
Sleep and locomotor activity patterns of flies were measured continuously. Briefly, flies were
individually placed into a 65mm glass tube that contains food at one end. Each tube containing
fly was then placed into Drosophila Activity Monitor (TriKinetics). Fly locomotor activity was
calculated from the number of times a fly crosses the midline of tube. Sleep was defined as a
period of quiescence that lasts for at least 5 minutes. Total sleep time, average sleep bout
duration and other sleep parameters were calculated using the Microsoft Excel.

Sleep deprivation and measurement of sleep rebound
Flies were individually placed into a 65mm glass tube that contains food at one end. Each tube
was then inserted into a vertical Drosophila Activity Monitor (TriKinetics). The sleep-nullifying
apparatus (SNAP) was used to sleep-deprive flies without activating stress response. The SNAP
tilts asymmetrically from -60° to +60° such that each fly is displaced during the downward
movement 10 times/minute. Following sleep deprivation, flies were allowed to recover. Sleep
rebound was calculated as % of sleep (min) gained during recovery periods in relative to baseline
sleep (min) divided by the total sleep (min) lost during sleep deprivation.

9

Measurement of arousal threshold
Flies were individually placed into a 65mm glass tube containing food. Each tube was inserted
into a vertical Drosophila Activity Monitor (TriKinetics) to continuously record locomotor
activity and sleep. The sleep-nullifying apparatus (SNAP) was used to perturb flies.
Arousal threshold was defined as the number of flies awakened when they were exposed to a
mechanical perturbation using the SNAP.

Aversive phototaxic suppression (APS) test
APS test is a learning assay that tests the ability of flies to learn to inhibit their affinity to light in
the presence of aversive stimulus, as previously described (Le Bourg and Buecher, 2002;
Seugnet et al., 2009b). Briefly, this assay uses a learning apparatus that contains two transparent
polystyrene vials vertically positioned at the end of the arms of the T-maze. One vial was lighted
by a fiber-optic light source (the lighted vial) while the other vial was covered by a gray plastic
cap such that no light can pass through (the darkened vial). During each learning test, a filter
paper of the lighted vial was wetted by 320μL of 1M Quinine hydrochloride (the aversive
stimulus in this assay) whereas that of the darkened vial was kept dry. Each fly was transferred to
the entrance of the T-maze, allowed to walk through the T-maze and choose between the lighted
and darkened vial. After each fly made a choice, the fly was removed from the vial and retransferred to the entrance of the maze for the subsequent trials. Each fly was tested in 4 blocks
of 16 trials. To avoid the effect of the right/left bias or the remaining odorous traces in the vial
choice, the location of lighted vial was altered as RRLLRRLLRRLLRRLL, where R and L
represent the lighted vial was on the right and left side of the maze, respectively. Time of
completion for 16 trials and their choice for each trial were recorded. Photopositive (P) was
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recorded when the fly chose the lighted vial whereas Photonegative (N) was recorded when the
fly chose the darkened vial. The leaning score was indicated by the number of photonegative
choices and calculated for 4 blocks of 4 trials. Microsoft Excel was used to calculate the average
and standard error of the mean (SEM). A higher learning score indicates good learning. Flies
(n>8) were tested for each conditions. Flies chose the darkened vial during the first block (first 4
trials) were excluded from further experiment since their low light sensitivity may affect the
choice in this assay.

Courtship conditioning assay
Courtship conditioning is an associative learning assay in which naïve male flies learn to inhibit
courtship behaviors by negative experience of rejection (Ganguly-Fitzgerald et al., 2006). This
assay is consisted of two components: training and memory evaluation. Depending on the
experimental design, generally, memory was evaluated at 48 hours following the training.
Briefly, a naïve male fly was exposed to a phenomenally feminized male fly (Tai2) in a 65mm
glass tube for a period of time (in total of 3 hours). During this “training” period, a naïve male
attempts to court with unreceptive Tai2 male but receives repeated rejections from Tai2 male.
Following the training period, a “trained” male fly was separated from the tai2 male and placed
to a new 65mm glass tube until the memory evaluation. During memory evaluation period, a
“trained” naïve was again exposed to a new Tai2 male in a 65mm tube for 10 minutes under the
video recording. The courtship index (CI), the time that the “trained” male spent in courtship
behaviors during the 10 minutes, was recorded. CI of “trained” male was compared to age and
genotype matched “naïve” male. The reduction in CI indicates memory.
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Modification of training methods in the “training” component of the courtship conditioning assay
induces different types of memory. 3 hours of consecutive training (a massed training) only
produces a short-term memory (STM) that cannot be detected at 48 hours following the training.
In contrast, three 1 hour- training that has 1 hour-rest in-between each training (a spaced
training) induces a long-term memory (LTM) that can be detected at 48 hours following the
training.
Statistics
We analyzed data using student-t test (two-tailed, unpaired). In all the experiments, P values less
than 0.05 are considered to be statistically significant.
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Results
PART I: Pharmacological method to induce a sleep-like state in flies.
1.1 Increased quiescence in CS flies following Gaboxadol treatment meets all of the
behavioral criteria of a spontaneous sleep.
Because the effect of Gaboxadol on sleep-like state in flies remains unknown, we
incorporated Gaboxadol (sigma-aldrich CAS#85118-33-8) into the flies food and measured
changes following treatment. We observed that quiescence in flies was increased in a Gaboxadol
dose-dependent manner following treatment (Figure 1a). In more detail, the observed increases
in quiescence were mostly during the day (Figure 1 b) than at night (Figure 1c) following
Gaboxadol treatment. Since flies sleep most of the night, less change in quiescence at night could
simply be due to the saturation effect. We also observed a slight increase in the average day and
night bout duration following Gaboxadol treatment (Figure 1 d and e). Gaboxadol has been
reported to increase slow wave sleep and maintain sleep in rats and human (Lancel, 1997;
Lundahl et al., 2007). Since the values for bout duration represent the length of an episode of a
sleep-like state, our observation that average night bout duration was increased following
0.1mg/mL Gaboxadol suggests the ability of Gaboxadol to maintain a sleep-like state in flies.

13
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In addition to EEG studies that dissect sleep into different stages, spontaneous sleep can
also be behaviorally defined (Hendricks et al., 2000a; Hendricks et al., 2000b). Behaviorally,
sleep is a state during which the quiescence and arousal threshold are increased. Sleep is a
rapidly reversible state, which distinguishes sleep from coma. Finally, sleep is homeostatically
regulated, that losing sleep increases the sleep needed to gain back the lost sleep. To address the
question that increased quiescence in CS flies following Gaboxadol treatment is equivalent to
spontaneous sleep, we further evaluated arousal threshold, rapid reversibility and homeostatic
response during increased quiescence following Gaboxadol treatment. To measure the arousal
threshold, we counted the number of sleeping flies that woke up by a mechanical disturbance.
We found similar levels of increased arousal threshold in flies during spontaneous sleep as
during the increased quiescence following 0.1mg/mL Gaboxadol treatment (Figure 2). Also, a
further increase in arousal threshold was observed during the increased quiescence following
0.5mg/mL Gaboxadol (Figure 2).
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The observation that flies respond to a mechanical disturbance during increased quiescence
following Gaboxadol treatment indicates that increased quiescence was rapidly reversible. To
determine if losing the increased quiescence mediates a homeostatic response, we sleep deprived
flies during Gaboxadol treatment and measured the presence of sleep rebound following sleep
deprivation. We found that when spontaneous sleep (Figure 3a) or increased quiescence (Figure
3b) following Gaboxadol in flies was lost by overnight sleep deprivation, flies exhibited an
increased sleep-like state following the sleep deprivation (Figure 3c and d).

Collectively, our results indicate that while quiescence and arousal threshold was
increased during the increased quiescence following Gaboxadol treatment, the increased
16

quiescence was rapidly reversible. The increased quiescence following 0.1mg/mL Gaboxadol
was regulated by homeostasis, as evidenced by the observation that flies exhibited sleep rebound
to recover a decrease in quiescence. Therefore, the increased quiescence following Gaboxadol
met all the behavioral criteria of spontaneous sleep.
1.2 Knockdown the expression of GABA receptors in the Mushroom Bodies and Clock cells
alters the response in flies following Gaboxadol treatment.
Gaboxadol targets δ-units of extra-synaptic GABAA receptors in mammals (Lancel,
1999; Winsky-Sommerer et al., 2007) . To determine if the increased quiescence following
Gaboxadol treatment is mediated through the activation of GABA receptors in flies
(Buckingham et al., 2005; Hosie et al., 1997), we used RNAi to knockdown the expression of six
GABA receptors; Lcch3, GRD, Rdl, GABABR1, GABABR2 and GABABR3, in the Mushroom
bodies (MB: 30y-) and Clock cells (c929) and evaluated the response in flies following
Gaboxadol treatment. We observed that knocking down the expression of Lcch3, GRD or
GABABR1 subunits in the MB (Figure 4 a) and clock cells (Figure 4 c) significantly reduced the
amount of increased quiescence following 0.1mg/mL Gaboxadol treatment. In addition, because
a GABAB agonist, SKF also increases quiescence in flies, we also evaluated the effect of the
GABA receptor knockdown on the response following SKF treatment. We observed that the
increased quiescence following SKF treatment was reduced if the expression of GABAB
receptors (R1, R2 and R3) were abolished in the MB (Figure 4 b). Knocking down expressions
of any six GABA receptors (Lcch3, GRD, Rdl, GABABR1, GABABR2 or GABABR3), in clock
cells had no effect on the response following SKF treatment (Figure 4d).

17

In sum, our results suggest that the expressions of three GABA receptors; Lcch3, GRD,
and GABABR1, in the MB and clock cells are required to mediate the increased quiescence
following Gaboxadol treatment.

18

1.3. Increased quiescence following Gaboxadol treatment facilitates a long-term memory
formation.
Flies form a long-term memory when sleep-like state was increased by genetic method
following a massed training protocol of Courtship conditioning that itself does not induce LTM
(Donlea et al., 2011). To determine if the increased quiescence following Gaboxadol treatment
facilitates a long-term memory formation, quiescence was increased for 4 hours by 0.1mg/mL
Gaboxadol treatment immediately following the massed training protocol and memories were
evaluated. No long-term memory was observed in flies following a massed training in the
absence of increased quiescence (Figure 5a). In contrast, a long-term memory was observed in
flies that had increased quiescence by Gaboxadol treatment following a massed training (Figure
5b).

Like spontaneous sleep, our observations suggest that increased quiescence by Gaboxadol
treatment has the ability to facilitate long-term memory formation.

19

1.4 Increased quiescence following Gaboxadol treatment does not enhance a short-term
memory in CS flies, but improves a short-term memory in learning mutants.
A short-term memory (STM) in flies can be evaluated using an APS test (Seugnet et al.,
2009b). Although CS flies learn normally in the APS test, we asked if additional quiescence
following Gaboxadol could make CS flies even better learners. The quiescence was increased in
CS flies for 2 days by Gaboxadol treatment prior to the APS test and learning was evaluated.
Increased quiescence following Gaboxadol in CS flies had no effect on their learning, as
evidenced by the observation that the performance of Gaboxadol-fed flies in the APS test was
similar to that of their age-matched non-drug-fed controls (Figure 6). While quiescence was
increased in CS flies following Gaboxadol treatment, the observation that the increased
quiescence did not enhance learning prompts us to hypothesize that the beneficial effect of the
increased quiescence on STM may be demands-specific.

20

A series of memory mutant flies were identified previously using a classic olfactory
learning paradigm (Boynton and Tully, 1992; Dura et al., 2007; Grotewiel et al., 1998; Mery et
al., 2007; Philip et al., 2001; Pinto et al., 1999; Qiu and Davis, 1993; Skoulakis and Davis, 1996;
Tully and Quinn, 1985). Among these mutants, we found nine mutant flies; rut2080, dunce, pst-1,
latheo, Leonardo, volado, lio, forS2 and dumb2, that also present learning impairment in the APS
test. We measured quiescence in these mutants following Gaboxadol treatment. As in CS flies
(Figure 7a), quiescence was increased in each mutant following Gaboxadol treatment (Figure 7bj).

21
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Except in dumb2 flies, the increased quiescence improved short-term memory in all the mutants
(rut2080, dunce, pst-1, latheo, Leonardo, volado, lio2) (Figure 8a and c-h). The beneficial effect
on short-term memory was mediated by increased quiescence, as supported by the observation
that no improvement in short-term memory was observed if flies were sleep-deprived during
Gaboxadol treatment (Figure 8a and c-h).
To further verify that the improvement of STM deficits is sleep-like state dependent,
sleep-like state was increased by genetic method (Donlea et al., 2011) using 104y>NachBac and
associated changes in memory were evaluated. We observed that STM deficits in rut2080 and
dunce were also reversed using 104y>NachBac (Figure 9a-b).

23
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1.5 Increased quiescence following Gaboxadol treatment may improve short-term memory
formation in Hydroxyurea (HU) treated CS flies.
Since lio2 flies present structural abnormality (Moreau-Fauvarque et al., 1998) and
Gaboxadol induced a sleep-like state that improved their learning, we further evaluated the effect
of increased quiescence on memory deficits caused by structural abnormality. Mushroom Bodies
(MB) is a critical structure in the flies brain (Strausfeld et al., 1998) that regulates both sleep
(Guo et al., 2011) and learning and memory (Akalal et al., 2006; Blum et al., 2009). Treatment
with Hydroxyurea (HU) in larvae chemically ablates MB; therefore HU-treated flies have a
reduced sleep-like state and are impaired in short-term memory formation (de Belle and
Heisenberg, 1994). Based on the role of MB in a sleep-like state and memory, we first
determined if the quiescence is increased in HU-treated CS flies following Gaboxadol treatment
and then evaluated short-term memory. Quiescence was increased by Gaboxadol treatment (data
not shown). While the increased quiescence improved short-term memory deficit in HU-treated
flies (Figure 10a), the increased quiescence did not improve long-term memory (Figure 10b-c).
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1.6 Increased quiescence following Gaboxadol improves long-term memory deficits in
period (per01) and blistered (bs1348) flies.
Since long-term memory formation following a spaced training is impaired in per01 and
bs1348 flies, we determined if increased quiescence following Gaboxadol treatment can rescue
LTM deficits in these flies. Quiescence in per01 and bs1348 flies were increased for 2 days by
Gaboxadol treatment prior to the spaced training, flies were removed from Gaboxadol food
during the training, and flies were placed back onto Gaboxadol food for 24 hours following the
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training. We observed that increased quiescence in per01 and bs1348 flies following Gaboxadol
treatment improved long-term memory deficits (Figure 11c-d and f-g).
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PART II: Study the role of sleep in memory consolidation using sleep-induction.
Since sleep is required to consolidate short-term memory, produced by massed training,
to a long-term memory that can be observed at 48 hours following the training, changing the
duration and timing of the induced sleep could further dissect the temporal relationship between
induced sleep and long-term memory formation. First, to address the question on how much
sleep is required to facilitate long-term memory formation, we determined the ability of a short
duration of induced sleep (<4hr) to consolidate memory (Result 2.1). Next, we evaluated if
modification in the timing of sleep induction is associated with changes in memory (Result 2.2).
Lastly, to challenge the hypothesis that sleep only passively protects memory from degradation
by simply acting as a shelter, we tested the ability of induced sleep to compensate sleepdeprivation-mediated memory interference (Result 2.3).
2.1: a short duration of an induced sleep-like state (<4hr) following learning is sufficient to
facilitate memory consolidation.
To address the effect of sleep duration on memory consolidation, we induced a shortduration (<4hr) of sleep using a genetic method (Donlea et al., 2011) in flies immediately
following the massed training protocol and then evaluated the memories at 48 hours after
training. Flies that slept for either 1 hour or 2 hours immediately following the massed training
were able to form a long-term memory (Figure 12 a-b), whereas flies that were only massed
trained without sleep exhibited no memory (data not shown). To further determine if the
beneficial effect on memory consolidation was sleep-dependent, we sleep-deprived flies while
the circuit was activated. We found that activation of the circuit alone produced no memory
(Figure 12c). Collectively, these data indicate that a short duration (<4hrs) of induced sleep was
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sufficient to consolidate memory. Importantly, sleep, rather than the activation of Fan-shaped
body alone, mediates the beneficial effect on memory consolidation.
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2.2 Sleep that is induced 24 hours after the training also facilitates memory consolidation.
In addition to determining the effect of sleep duration on memory consolidation, we also
examined the effect of sleep timing on memory consolidation. 4 hours of sleep were induced in
flies at 24 hours following massed training and memories were evaluated. We found that flies
that slept for 4 hours post massed training presented a long-term memory (Figure 13a). Notably,
we observed that 2 hours of sleep at 24 hour after the massed training also facilitated long-term
memory formation (Figure 13b). Collectively, these results suggest the ability of induced sleep to
facilitate memory consolidation even when it is introduced at a later time.
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2.3 Sleep plays an “active” role in memory consolidation: 4 hours of induced sleep
compensates the memory interference caused by sleep deprivation.
A memory system contains three consecutive stages: encoding, consolidation and
retrieval. During encoding stage, information through sensory inputs is converted to a memory
trace which is susceptible to incoming interference. The newly formed memory trace is stabilized
during the consolidation process and is being stored until the retrieval stage at when the stored
memory is recalled. Despite the involvement of sleep in the memory consolidation process,
sleep’s role in memory consolidation remains the center of debate. Two hypotheses (Ellenbogen
et al., 2006a; Ellenbogen et al., 2006b)have been proposed for how sleep is involved in memory
consolidation. The “passive” hypothesis posits that sleep passively protects memory from
degradation by serving as a temporal shelter from any negative effect of ongoing cognitive
activity. In contrast, the “active” hypothesis argues that sleep can either directly or indirectly
trigger the memory consolidation process in addition to supplying the reduced interference
period.
Whether sleep facilitates memory consolidation by only supplying the reduced
interference period remains to be defined. Our observation that induced sleep at later time also
facilitates memory consolidation (section 2.2) supports the notion that sleep may have an “active”
role in memory consolidation, rather than sleep only acts as a shelter of interference. To address
this question, we determined the effect of induced sleep on a long-term memory formation
following the interference period caused by sleep-deprivation. It is quite established idea that
sleep deprivation has a negative impact in memory consolidation. A work in flies also
demonstrated that sleep deprivation after the training abolishes the ability to form a long-term
memory (Ganguly-Fitzgerald et al., 2006). Flies did not form a long-term memory when sleep31

like state was increased for 4 hours following 4hours of sleep deprivation (Figure 14a).
Increasing sleep-like state for 4 hours following 2 hours of sleep deprivation may permit the
expression of LTM (Figure 14b).
Together, these results suggest that memory consolidation during sleep is more likely an
active process rather than a passive state in which sleep only provides a time of reduced
interference.
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Discussion
We observed that quiescence in flies was increased by Gaboxadol treatment. The increase
in quiescence was mediated by the action of Gaboxadol through GABA receptors in flies. The
increased quiescence following Gaboxadol treatment met all the behavioral criteria of a
spontaneous sleep-like state in flies. The function of increased quiescence in memory was
evidenced by the observation that LTM was formed in flies when the quiescence was increased
by Gaboxadol treatment following a massed training that itself does not induce LTM. Together,
our observations suggest that the increased quiescence observed in flies following Gaboxadol
treatment is behaviorally and functionally equivalent to the spontaneous sleep-like state.
Therefore, Gaboxadol can be used to induce a sleep-like state in flies. Sleep induction using
drugs does not require genetic crosses; thereby it is more technically convenient and allows
further application such as high-throughput screening.
Although drug treatments often cause anesthesia, our observations suggest that increased
quiescence following Gaboxadol treatment is a sleep-like state rather than an amnestic effect of
Gaboxadol. First, the increased quiescence was rapidly reversible as evidenced by the
observation that the ability of flies to respond to a mechanical SNAP was not altered by the
Gaboxadol treatment. External stimulus mediated rapid transition between a sleep and wake state
which is a distinguished feature found only in sleep not in coma state. Second, the increased
quiescence was regulated by homeostasis. Third, the ability of increased quiescence to facilitate
memory formation is sleep-dependent, as evidenced by the observation that memory formation
was disrupted when flies were sleep-deprived while they were on Gaboxadol. The ability of
anesthesia to enhance memory consolidation has not been reported.
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The hypothesis that additional sleep-like state following Gaboxadol treatment mediates
beneficial effect on memory formation was further supported by our observation that increased
sleep-like state following sleep induction using genetics also facilitated memory formation.
Therefore, using both methods of sleep induction, we demonstrated the ability of sleep-like state
to facilitate memory formation in flies.
Furthermore, our observations that increased quiescence in flies following Gaboxadol
treatment rescued STM and LTM deficits in memory mutants suggest the therapeutic role of
additional sleep in memory deficit. In flies, most memory formation, if not for all, requires the
Mushroom bodies (MB), a structure in flies brain that is analogous to the hippocampus in
mammals (Davis, 1993). The excitatory cAMP/PKA signaling in MB is critical for learning and
memory and gene mutations that alter the cellular cAMP level lead to memory impairment as
observed in rut2080 and dunce flies (Davis et al., 1995). In addition, MB is also innervated by
GABAergic neurons (Yasuyama et al., 2002) and inhibitory GABAergic signaling is as
important as cAMP signaling in learning and memory (Busto et al., 2010; Liu and Davis, 2009).
The proper interaction and balance between the two signals may be important for memory
formation, as that alternation in cAMP signaling-mediated suppression of GABAergic inhibition
could underline the cognitive impairments in memory mutants. Because cAMP-PKA pathway in
MB also is implicated in sleep (Chen et al., 2013; Hendricks et al., 2001; Joiner et al., 2006), it is
possible that changes in sleep may modulate cAMP-PKA pathway. Therefore, reversal of STM
deficits in rut2080 and dunce flies could be mediated by the ability of increased sleep-like state
following Gaboxadol or genetic treatment to compensate the reduction in cAMP-mediated
suppression of GABAergic inhibition.
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Memory in flies is also affected by genes that are not in the cAMP/PKA pathway, as flies
with mutations in these genes also present memory impairment (Kahsai and Zars, 2011).
Importantly, sleep-like state in flies is also regulated by various genes, pathways and brain
regions (Bushey and Cirelli, 2011; Ishimoto et al., 2012). Our observation that increased sleeplike state reversed STM deficits in pst-1, latheo, Leonardo, volado, lio2 flies supports the ability
of sleep to induce global effect on memory, as a result of sleep-mediated changes in expression
level of genes and protein, and the changes in excitability within and the connection between
neuronal circuits that are implicated in memory. Therefore, further studies that identify the
changes in gene transcription level and excitability of neuronal circuit that are associated with
modification of sleep would further dissect the connection between sleep and memory.
In addition, dopamine neurons are involved in the presentation of aversive information to
the MB during olfactory learning (Mao and Davis, 2009). Our observation that STM deficit in
dumb2 mutant was not reversed by the increased sleep-like state supports this function of
dopamine neurons. The function of dDA1 receptor is abolished due to the gene mutation in
dumb2 mutant, STM deficit could not be reversed simply because there is no learning to begin
with.
Moreover, our observation additional sleep rescues the STM deficit in MB ablated flies
was intriguing, given the role of MB in learning and memory (Davis, 1993; Keene and Waddell,
2007; Zars, 2000). This observation may suggest that additional sleep can bypass MB and permit
the expression of memory by the activation of other process, such as transcriptional regulation of
genes that are involved in memory. However, our results could be misleading by the incomplete
ablation of MB following hydroxyl-urea treatment. MB contains approximately 5000 Kenyon
cells (2500 per hemisphere) that are divided into three lobes: α/β, α’/β’ and ϒ (Crittenden et al.,
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1998). Each lobe is implicated in different process of memory (Blum et al., 2009; Davis, 2011;
Krashes et al., 2007; McGuire et al., 2001). Further studies that examine the correlation between
degree of MB ablation and memory performance in individual fly could address the role of sleep
in memory in the absence of MB.
Because the sleep induction method allows for a temporal control of additional sleep, we
evaluated if modifications to the duration and timing of additional sleep was associated with
changes in memory. 4 hours of increased spontaneous sleep seems to be required for a long-term
memory formation following a spaced training (Ganguly-Fitzgerald et al., 2006). Our
observation that even a short duration (<4 hour) of additional sleep facilitated memory suggest
the hypothesis that induced sleep may be better than spontaneous sleep. Studies that compare the
length that memory can last following induced sleep and spontaneous sleep is one approach to
test this hypothesis. Results from further studies could address the effect of sleep quality on
memory consolidation.
Finally, whether sleep passively or actively affects the memory consolidation process
remains to be the center of debate. We observed that additional sleep following an interference
period, either it occurred naturally or artificially by sleep deprivation, had ability to consolidate
memory. Therefore, our results support the active roles of sleep in memory consolidation. In line
with our observations, the active roles of sleep are also demonstrated in other biological
processes. Sleep regulates brain mechanism in metabolites clearance (Xie et al., 2013) and also
regulates transcription of genes including those involved in metabolism (Moller-Levet et al.,
2013).
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Chapter 2
The Role of Alpha-synuclein in Fatty Acid Metabolism
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Abstract
Introduction: Accumulation of aggregated alpha-synuclein protein is the defining pathologic
feature of Parkinson’s disease (PD). However, the molecular mechanisms underlying protein
aggregation remain to be defined. Because the physiological function of alpha-synuclein remains
unclear and previous studies have indicated a role in fatty acid metabolism and specifically acyl
CoA synthesis, further studies that examine the interaction of alpha-synuclein with free fatty
acids could provide a better understanding of the protein’s normal function.
Method: We examined the interaction of alpha-synuclein with oleic acid, a monounsaturated
free fatty acid, using a scintillation proximity assay (SPA). We characterized the regions of
alpha-synuclein protein that are required for oleic acid binding using mutagenesis studies. We
over-expressed alpha-synuclein in HEK293FT cells and measured its effect on the rate at which
oleic acid is incorporated into phospholipids, which is determined by the rate at which oleic acid
is converted to oleyl CoA by acyl CoA synthetase enzymes.
Results: We found that alpha-synuclein cooperatively binds to monomeric oleic acid. Mutations
that change either amino acids 30 or 46 in the alpha-synuclein protein disrupt the alphasynuclein-oleic acid interaction. Over-expression of WT alpha-synuclein, but not A30P alphasynuclein, in HEK293FT cells increased the rate of oleic acid incorporation into
phosphatidylcholine (PC).
Discussion: SPA is a novel approach to characterize the binding of alpha-synuclein to oleic acids.
Alpha-synuclein promotes an increase in the oleic acid incorporation rate in HEK293FT cells.
The absence of oleic acid binding by A30P alpha-synuclein and the corresponding absence of an
effect of A30P alpha-synuclein on the incorporation rate in cells further supports the hypothesis
that alpha-synuclein promotes acyl CoA synthesis by binding to free fatty acids.
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Introduction
The defining pathologic change in Parkinson disease (PD) is the accumulation of aggregated
alpha-synuclein protein in Lewy bodies and neurites. Alpha-synuclein is a soluble 140-aminoacid protein expressed throughout the central nervous system with predominant localization to
the presynaptic terminals of neurons (Iwai et al., 1995; Maroteaux et al., 1988). The structure of
the protein contains three distinct domains: the N-terminus domain, the internal hydrophobic
NAC domain and the C-terminus domain. The N-terminus (residues 1-60) contains seven
imperfect repeats (KTKEGV) that form alpha-helical secondary structure upon interaction with
phospholipid vesicles and micelles in vitro (Bisaglia et al., 2005; Chandra et al., 2003; Davidson
et al., 1998; Ulmer et al., 2005) The internal hydrophobic NAC domain (residues 61-95)
participates in self-aggregation of the protein to form fibrils that are rich in β-sheet secondary
structure (Ueda et al., 1993). The C-terminus (residues 96-140) provides structural flexibility to
the protein.
While alpha-synuclein gene mutations, including gene multiplication and point mutations,
cause rare familial forms of PD (Chartier-Harlin et al., 2004; Ikeuchi et al., 2008; Kiely et al.,
2013; Kruger et al., 1998; Polymeropoulos et al., 1997; Proukakis et al., 2013; Singleton et al.,
2003; Zarranz et al., 2004), most cases of PD are sporadic and related to a combination of
genetic and environmental risk factors. The self-aggregation of alpha-synuclein to form fibrils is
observed in all PD cases and several other neurodegenerative disorders (REF). The molecular
mechanisms underlying protein aggregation remain to be defined. It is possible that alteration in
normal function of the protein could change protein structure to the conformational state that is
prone to aggregate. Because the physiological function of the alpha-synuclein protein remains
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elusive, further studies that identify the normal function of the protein could also aid the
understanding on the self-aggregation property of the protein.
Among many proposed normal functions of alpha-synuclein, the interaction of alphasynuclein with fatty acids has been observed in both in vitro (Assayag et al., 2007; Broersen et
al., 2006; De Franceschi et al., 2009; Karube et al., 2008; Lucke et al., 2006; Perrin et al., 2001;
Sharon et al., 2003; Sharon et al., 2001; Varkey et al., 2013) and in vivo studies (Golovko et al.,
2005; Golovko et al., 2006; Golovko et al., 2007). Alpha-synuclein hinders the formation of fatty
acid micelles in vitro (Broersen et al., 2006; De Franceschi et al., 2009). In vivo studies of alphasynuclein-KO mice revealed that fatty acid metabolism, specifically the incorporation rate of free
fatty acids into brain lipids, is altered in the absence of the alpha-synuclein gene (Golovko et al.,
2005; Golovko et al., 2007). Furthermore, a recent population-based study reported that
increased dietary intake of fatty acids lowers the risk of developing PD (de Lau et al., 2005).
Together these studies suggest that the regulation of fatty acid metabolism could be a normal
function of alpha-synuclein protein. Importantly, the notion that alpha-synuclein regulates fatty
acid metabolism could explain our recent observation that alpha-synuclein overexpression
improves motor deficit of pla2g6-KO mice, an animal model of Infantile neuroaxonal dystrophy
(INAD).
Infantile neuroaxonal dystrophy (INAD) is a fatal progressive neurodegenerative disorder
for which there is currently no treatment. Onset of INAD typically occurs in early childhood and
INAD patients display progressive motor, sensory and cognitive impairment (Farina et al., 1999;
Nardocci et al., 1999). The defining histopathologic changes in INAD include the accumulation
of alpha-synuclein in Lewy bodies and neurites, and the presence of neuroaxonal spheroids
containing tubulovesicular membranes in axons and dendrites throughout the nervous system
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(Newell et al., 1999; Riku et al., 2013; Simonati et al., 1999; Wakabayashi et al., 2000). Notably,
mutations in the PLA2G6 gene (chromosome 22q12-q13) which encodes Ca2+ independent
phospholipase A2β (iPLA2β) are identified in most INAD patients (Gregory et al., 2008; Morgan
et al., 2006). This enzyme was originally identified in the Chinese hamster ovary (CHO) cell line
based on its ability to hydrolyze sn-2 ester bond of phospholipids to release free fatty acids and
lysophospholipids (Wolf and Gross, 1996).

The molecular mechanisms underlying neurodegeneration in INAD remain to be defined.
Because pla2g6 mutations abolish the ability of the enzyme to produce free fatty acids from the
hydrolysis of phospholipids (Engel et al., 2010), and because fatty acids are involved in many
metabolic processes, the deficiency in fatty acid production caused by Pla2g6 mutations may be
central to the pathogenesis of INAD. To better understand the mechanism by which Pla2g6
dysfunction causes neurodegeneration, Pla2g6-KO mice were generated by Neo gene insertion at
exon 9 (Bao et al., 2004). Pla2g6-KO mice replicate both behavioral and histopathological
features of human INAD including progressive motor impairment and neuroaxonal spheroid
formation throughout the nervous system (Malik et al., 2008). Compared to WT mice, Pla2g6KO mice present an age-dependent impairment in rotarod test (Malik et al., 2008). To further
investigate the role of alpha-synuclein protein aggregation observed in INAD, human WT alphasynuclein was overexpressed in Pla2g6-KO mice. Interestingly, overexpression of human-WTalpha-synuclein significantly improved motor deficits in Pla2g6-KO mice (unpublished data).
Fatty acid metabolism is essential to many downstream metabolic processes, including
storage of energy in the form of triglycerides, production of energy through beta-oxidation, new
lipid synthesis and remodeling and signaling (Black et al., 2000; Grintal et al., 2009; Miller et al.,
1987; Rapoport, 2001; Tol, 1975). The sources of the free fatty acids come from both outside
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and inside of the cells. Free fatty acids from dietary intake enter cells either by passive diffusion
through the cell membrane or via flip-flop mechanism, which may be aided by FABP mediated
transport (Hamilton and Brunaldi, 2007). Inside cells, free fatty acids are generated by a variety
of lipase enzymes that release free fatty acids from phospholipids and other lipid classes. Finally,
free fatty acids, or specifically acyl CoAs are produced by fatty acid synthase through the de
novo fatty acid synthesis pathway that includes desaturation and elongation reactions. In order to
be utilized in downstream metabolic processes, almost all free fatty acids must be activated by
acyl CoA synthetase (ACS) enzymes to form Acyl-CoAs (Soupene and Kuypers, 2008). Pla2g6
mutations that impair catalytic activity may alter fatty acid metabolism by reducing the free fatty
acid pools that are available for activation. Therefore, approaches that increase the efficiency of
fatty acid activation could correct the altered fatty acid metabolism by compensating for
impaired free fatty acid production.
Based on the previous observation that fatty acid incorporation rates were reduced in the
absence of alpha-synuclein gene (Golovko et al., 2005; Golovko et al., 2007), and our
observation that human WT-alpha-synuclein increases the catalytic rate of ACS enzymes in vitro
(unpublished), we hypothesized that the protective effect of alpha-synuclein in Pla2g6-KO mice
is mediated by increased conversion of fatty acids to fatty-acyl-CoAs, which compensates for
impaired fatty acid production caused by Pla2g6 mutations. Further studies that examine the
alpha-synuclein-fatty acid interaction could begin to address this hypothesis.
Since previous studies examining a direct interaction between alpha-synuclein and fatty
acids have generated inconsistent results (Golovko et al., 2005; Karube et al., 2008; Sharon et al.,
2001), in the first part of our study, we characterized the binding of alpha-synuclein to free fatty
acids using a scintillation proximity assay (SPA). Because the N-terminus of the protein has been
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reported to mediate binding to phospholipid vesicles and micelles (Chandra et al., 2003;
Davidson et al., 1998; de Laureto et al., 2006; Eliezer et al., 2001; Ulmer et al., 2005; Varkey et
al., 2013) and because the N-terminus of the protein hosts the identified point mutants that are
associated with familial PD (Kiely et al., 2013; Kruger et al., 1998; Polymeropoulos et al., 1997;
Proukakis et al., 2013; Zarranz et al., 2004), in the second part of our study, we characterized the
regions of alpha-synuclein protein that are required for oleic acid binding using mutagenesis
studies. Lastly, to determine if alpha-synuclein overexpression promotes fatty acid metabolism in
cell culture, we measured the effect of alpha-synuclein overexpression on the fatty acid
incorporation rate in HEK293FT cells.
Together, findings from this study will provide a better understanding about the direct
interaction of alpha-synuclein with free fatty acids, and the effect of alpha-synuclein-fatty acid
interaction on fatty acid metabolism. Given that fatty acids are involved in many metabolic
processes, and that the normal function of alpha-synuclein is unknown, findings on the alphasynuclein-fatty acid interaction could ultimately contribute to a better understanding of the
physiological function of the protein.
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Materials and Methods
Recombinant protein expression and purification
To produce each recombinant alpha-synuclein protein, BL21 (DE3) competent cell was
transformed with pRK172 plasmids containing human WT or mutant alpha-synuclein. Control
protein was generated from BL21 cells transformed with an empty expression plasmid as
described (Bagchi et al., 2013). The colony containing each construct of plasmid DNA was
picked and inoculated in TB media at 37°C for 16 hours prior to purification. The cells were
harvested by centrifugation at 3900 xg for 10 minutes at 25°C. The supernatant was discarded.
To lyse the cells, the pellet (cells) was resuspended in 20mL of osmotic shock buffer (30mM
Tris-HCl, 2mM EDTA, 40% sucrose pH7.2), incubated in the buffer at room temperature for 10
minutes and collected by centrifugation at 8000 xg for 10 minutes at 25°C. The outer cell
membrane was removed by resuspention and incubation (3 minutes on ice) of the pellet in icecold MQ water and 2M MgCl2, followed by centrifugation at 20,000xg for 15 minutes at 4°C.
The supernatant (periplasmic) was collected and DNA was precipitated by addition of
streptomycin mixture and centrifugation at 20,000xg for 15 minutes at 4°C. The supernatant was
heated at 95°C water bath for 10 minutes to further separate alpha-synuclein protein from other
proteins. To further increase the purity of alpha-synuclein, the supernatant was filtered with
0.45µm filter and loaded onto a chromatography column (Bio-Rad Laboratories) containing 1mL
of DEAE sepharose beads (Sigma) in 20mM Tris-HCl and 1mM EDTA. Each column was
washed with 10mL of ice-cold wash buffer (20mM Tris-HCl pH8, 1mM EDTA and 1mM DTT)
and each alpha-synuclein protein was eluted with 0.3M NaCl elution buffer (20mM Tris-HCl
pH8, 1mM EDTA, 1mM DTT and 0.3M NaCl). The elutant was dialyzed overnight in 5L of
dialysis buffer. The protein concentration of each construct was measured using BCA assay.
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Mutagenesis
Forward and reverse primers for each construct were designed using online program (Agilent
technologies) and ordered from integrated DNA technologies. Using the QuikChange sitedirected mutagenesis (Agilent technology Inc), each alpha-synuclein mutant was created by a
single amino acid mutation onto the His-tagged WT alpha-synuclein-pRK172 plasmid (Table 1).
Nucleotide

Amino acid

location

substitution

A30P-alpha-syn pRK172

88

G to C

E46K-alpha-syn pRK172

188

G to A

H50Q-alpha-syn pRK172

150

T to G

G51D-alpha-syn pRK172

152

G to A

A53T-alpha-syn pRK172

209

G to A

WT-alpha-syn pRK172

Each plasmid was transformed into DH5α competent cells for DNA expression. Plasmid DNAs
from the competent cells were purified using the QIAprep®Spin Miniprep Kit following the
manufacture’s protocol (Qiagen). The concentrations of purified plasmid DNA were determined
by measuring absorption at 260 nm using NanoDrop spectrophotometer. Nucleotide sequences of
all plasmids were confirmed by DNA sequencing.
Scintillation Proximity Assay (SPA)-binding assay
The binding interaction of alpha-synuclein with oleic acid was examined using Scintillation
Proximity Assay. Chelated copper PVT SPA beads (PerkinElmer) and purified his-tagged empty
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vector/alpha-synuclein proteins were diluted in 30mM Tris-HCl pH7.4 buffer such that the final
concentrations of SPA bead and protein were 0.2mg/mL and 4µg/mL, respectively. 3H-labeled
oleic acid (American radiolabeled chmicals Inc) was mixed with unlabeled oleic acid at a ratio of
1:100. Oleic acid was first diluted in DMSO to 100x of each final concentration, and then diluted
in 30mM Tris-HCl pH7.4 buffer to the final concentration of 0.5, 2, 3.5, 5, 6.5, 7 and 8µM. To
reduce the non-specific binding of protein to the plastic plate, each well of the 96-well
microplate was coated with 200µL of 0.02% gelatin (Sigma) and incubated at 37°C for 30
minutes prior to each experiment. 0.02% gelatin was aspirated and each well was washed twice
with 200µL of MQ water. We first added 25µL of SPA beads to each well, and then we added
25µL of either control protein or alpha-synuclein protein. 50µL of oleic acid mixture at different
concentrations were added to each well as the last component. The plate was sealed with
adhesive plastic film and incubated at 37°C for 2 hours. The plate was cooled to room
temperature for 10 minutes before it was read in the MicroBeta scintillation counter
(Perkinelmer).
We plotted count per minutes (cpm) detected at the different concentrations of oleic acid. Bmax,
Kd, and hill constant were determined using nonlinear regression by fitting the data to a one-site
binding model with hill slope:
(y= Bmax*Xh/Kdh+Xh).
Bmax = the concentration of oleic acid at which the binding sites on the receptors are 100%
occupied.
Kd = the concentration of oleic acid at which half of the binding sites on the receptors are
occupied.
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Hill constant = the degree of co-operativity

Dynamic Light Scattering (DLS)
We determined critical micelle concentration (CMC) of oleic acid using Dynamic light scattering.
Various concentrations of oleic acid were prepared by dissolving oleic acid in 30mM Tris-HCl
pH7.4 buffer. The intensity of scattered light at each concentration was measured at 25°C using
Nano ZS (Malvern Instrument, UK) with a measurement angle of 173°.
Transfection in HEK293FT cells
HEK293 cells were maintained in complete DMEM media (DMEM, 10% FBS, L-Glutamine and
Penicillin/Streptomycin) in T-75 flasks. Cells in the flask were briefly washed with 5mL of PBS
and dislodged with 1mL of Trypsin. The action of trypsin was stopped by adding 4mL of
complete DMEM media (10% FBS, L-glutamine, NO antibiotics) into the flask. The cells were
resuspended thoroughly in order to obtain a single-cell suspension and were transferred into a
new 50mL Falcon tube (ALL tube). To prepare the cell sample for counting (COUNT tube),
0.5mL of cell suspension was added into a new 50mL Falcon tube containing 4.5mL complete
DMEM media (10%FBS, L-glutamine, NO antibiotics). Cell numbers were determined by
counting cells using a hemocytometer. Cells were transfected in 6-well plate. To enhance the
adhesion of cells onto the wells, each well was coated with 500µL of 1xPoly-D-Lysine
Hydrobromide (sigma #P1149) for 2 hours prior to the transfection. HEK293 cells were
transfected with either pcDNA3.1 Vector maxi or WT/mutant alpha-synuclein using
Lipofectamine2000. The cells were incubated in DNA/Lipofectamine mixture (state the amount
of DNA, lipofectamine, and number of cells per well) overnight at 37°C. The morning after
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transfection, the media was changed to complete DMEM media with 10% FBS (DMEM,
10%FBS, L-glutamine, Penicillin/Streptomycin).
14

C Oleic acid pulse-labeling

HEK 293 cells were maintained in complete DMEM media with 10% FBS (DMEM, 10%FBS,
L-glutamine, Penicillin/Streptomycin). 2 hours prior to the pulse-labeling, the media was
changed to the complete media with 2% dialyzed FBS (DMEM, 2% Dialyzed FBS, L-glutamine
and Penicillin/Streptomycin). The pulse-solution containing 1mM fatty-acid free BSA, 14C-oleic
acid and TBS (10mM Tris and 150mM NaCl) was prepared fresh and incubated at 37°C for 30
minutes before pulsing the cells. To pulse-label the cells, 1mL of media was removed and 10µL
of pulse-solution was added to each well. The plate was incubated at 37°C for 15 minutes.
Cell harvesting and extraction
Immediately following the 15 minutes pulse-labeling, the cells were harvested in ice-cold 1xPBS.
The cells were removed from each well and transferred into respective 1.5mL Eppendorf tubes.
Cells were collected by centrifugation at 5000xg for 1minute at 4°C. The supernatant was gently
removed from each tube and remaining PBS was removed by additional centrifugation at 5000xg
for 30 second at 4°C. The cells were resuspended gently in 50µL ice-cold 1xPBS. 5µL of
resuspended cells were transferred to a new 1.5mL Eppendorf tube and saved for BCA and
ELISA assay. The remaining 45µL of resuspended cells was processed for extraction. To extract
lipid from the cells, we used chloroform/methanol/water extraction procedure (Bligh and Dyer,
1959). Briefly, 3.3 volumes (148.5µL) of 1:2 chloroform/methanol, 1.1 volume (49.5µL) of
chloroform and 1 volume (45µL) of MQ water was added to each tube containing 45µL of
resuspended cells in order. The tubes were vortexed after each addition. Following centrifugation
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at 2000rpm at 25°C for 5minutes, separation into two phases (top aqueous and bottom organic
phase) was observed. Both aqueous and organic phases were carefully removed and transferred
into respective 1.5mL Eppendorf tubes. The bottom organic phase was used for TLC analysis.
Thin Layer Chromatography (TLC)
To separate each species in the extracted organic phase, 10μL of cell suspension from each
sample plus four lipid standards (14C-PC, 14C-LPC, 14C-acyl-CoA and 14C-Oleic acid) were
applied onto a silica gel coated glass plate. The TLC plate was developed in the
Chloroform/methanol/water (65/25/4) system and visualized using a FLA-7000 phosphoimager
(Fuji). The radioactive intensity of each spot was determined using Multigauge software (Fuji).
Micro BCA Protein Assay
5μL of resuspended cell extract were dissolved in 45μL of TBS (25mM Tris-HCl pH8 and
150mM NaCl) buffer+1%Triton X and sonicated in a water bath for 1 minute. We used a BCA
assay Kit (Thermo scientific) to quantify the total concentration of protein in each sample.
Sandwich Enzyme linked Immunosorbent assay (ELISA)
We used sandwich ELISA to detect the level of alpha-synuclein expression in each sample. Each
well of the microtiter plate was coated with 50µL of carbonate coating buffer containing capture
antibody (1µg/mL Asyn-211) and incubated overnight at 4°C. The following day, each well was
washed 5 times with 1xPBS-tween 20 (150µL) and patted on a paper towel to remove the
residual coating mixture. Protein-binding sites in each coated well were blocked with 150µL of
blocking buffer (2% BSA-PBS) and incubated for 2 hours at 37°C. During the incubation we
prepared samples for the standard curve by dilution of each purified recombinant alpha-synuclein
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protein in the sample buffer (300mM Tris-HCl pH8, 0.25% BSA, 1X aprotinin, 1x Leupeptin
and 0.1% triton in PBS) to the final concentration of 0, 0.1, 0.3, 0.9, 2.7, 8.1, 24.3 and
72.8ng/mL. The 1000-fold diluted unknown sample and samples for the standard curve were
loaded to each respective well, and the plate was incubated overnight at room temperature. Next
day, each well was incubated with the detection antibody (1µg/mL FL-140) and then secondary
antibody (HRP-anti rabbit), followed by detection with TMB and measurement of absorbance at
650 nm.

Statistics
We analyzed data using student-t test (two-tailed, unpaired). In all the experiments, P values less
than 0.05 are considered to be statistically significant.
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Results
1.1 Alpha-synuclein cooperatively interacts with monomeric fatty acid.
We determined the binding of alpha-synuclein to oleic acid using a scintillation proximity
assay (SPA). Recombinant human WT alpha-synuclein protein was purified using previously
established method (Bagchi et al., 2013). The purified recombinant protein migrates as a single
peak with a relative molecular weight of 57 kD in size-exclusion chromatography under native
conditions. Using static light scattering (SLS), we also found the size of the purified recombinant
protein to be around 57±7.27 kDa, consistent with the previously reported size of monomeric
protein. To determine the interaction of alpha-synuclein with oleic acid, purified his-taggedhuman WT-alpha-synuclein protein was incubated with a range of different concentrations of 3Hlabeled oleic acid in the presence of chelated copper PVT beads. Because 3H oleic acid may
interact directly with SPA beads, nonspecific binding was determined in parallel reactions
containing oleic acid and beads without recombinant alpha-synuclein. We calculated the alphasynuclein dependent binding at each oleic acid concentration by subtracting the non-specific
binding from the total binding. A saturation binding curve was generated by plotting the specific
binding versus the oleic acid concentration (Figure 1). Interestingly, we observed a sigmoidal
relationship between specific binding values and oleic acid concentration, indicating cooperative
binding of alpha-synuclein to oleic acid. We analyzed the data by fitting the curve to the
equation using non-linear regression and obtained Kd, Bmax and Hill coefficient values. We
observed specific binding of alpha-synuclein to oleic acid with a Kd of 4.27 μM, a Bmax of
2599.25 cpm and a Hill coefficient of 4.83. Notably, these binding values were consistent across
multiple independent sets of experiment. Because the hill coefficient represents the degree of
cooperativity and values of hill coefficient >1 indicate positive cooperativity, these results
support cooperative binding of oleic acid to alpha-synuclein.
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Figure 1. Alpha-synuclein cooperatively binds to oleic acid. The binding interaction of alphasynuclein with oleic acid was characterized using scintillation proximity assay (SPA) at a range
of different oleic acid concentrations (0-8μM).
Fatty acids are amphiphilic molecules that contain hydrophobic tails and hydrophilic
heads, which can aggregate to form micelles, similar to other surfactants. The concentration
above which fatty acids form micelles is defined as the critical micelle concentration (CMC).
Because oleic acid can form micelles and because alpha-synuclein has been observed to interact
with SDS micelles in vitro (Bisaglia et al., 2005; Ulmer et al., 2005), we investigated the
properties of oleic acid over the range of concentrations used in the binding assay, to further
understand the nature of the alpha-synuclein-oleic acid complex. To determine whether the
observed binding interaction was mediated by the binding of alpha-synuclein to monomeric oleic
acid or to oleic acid micelles, we evaluated the CMC of oleic acid using Dynamic Light
Scattering (DLS). Based on the principle that micelles can be detected by a change in light
scattering properties relative to monomeric oleic acid (Davis et al., 2011), we measured light
scattering intensity over a range of different concentrations of oleic acid. The estimated CMC of
oleic acid in our assay was 30 μM (Figure 2). This result indicates that at the concentrations
(<10µM) examined in the SPA assay, oleic acid molecules are in a monomeric state. Thus, the

62

binding observed in the SPA assay represents the interaction between alpha-synuclein and
monomeric oleic acid molecules rather than micelles.

Figure 2. Determination of critical micelle concentration (CMC) of oleic acid. The size of
oleic acid was measured using dynamic light scattering (DLS) across different oleic acid
concentrations (0-200μM). No significant light scattering was detected below 30μM, however, a
linear increase in light scattering was observed beyond 30μM (Figure 2a). A line was plotted
using the four oleic acid concentrations (50, 100, 150 and 200μM) at which changes in light
scattering were observed (Figure 2b). CMC of oleic acid was estimated by finding the xintercept of the line. Consistent results were obtained across multiple independent experiments.

Because we can mathematically calculate the mass of oleic acid at the concentration
where all the binding sites on alpha-synuclein were occupied (Bmax), we estimated the mass ratio
of alpha-synuclein and oleic acid in the complex. A critical factor in this calculation is the
determination of counting efficiency needed to determine disintegrations per minute (dpm) from
counts per minute (cpm). Due to the decay energy of the isotope, the counting efficiency of 3H
using scintillation fluid is 42%. The counting efficiency of PVT-SPA beads has been estimated
at 10% based on data in Dr. Kotzbauer’s lab comparing SPA to filter binding assays for 3Hlabeled ligands that bind to alpha-synuclein fibrils (Liu, J., Dhavale, D. and Kotzbauer, P.,
unpublished). Therefore, we estimated the overall counting efficiency of the assay to be 5%. The
average Bmax value from multiple experiments was 2599.25 cpm, Using our estimated counting
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efficiency (= cpm/dpm) of 5%, we obtained the average Bmax value of 51985 dpm. The average
Bmax value (in dpm) was further converted to millimoles by first converting dpm to Curie (since
1Ci = 2.22x1012, 51985 dpm / (2.22x1012dmp/Ci) =2.34x10-8 Ci), and specific activity
(60Ci/mmole for 3H oleic acid 2.34x10-8 Ci / (60Ci/mmole) = 3.90x10-10 mmole) was used for
conversion to mmoles. Because 3H-labeled oleic acid was diluted 100 fold with unlabeled oleic
acid in the assay, we multiplied the value by 100 and found an average of 39 pmole oleic acid at
Bmax. Given that each reaction contains 28 pmole of WT alpha-synuclein, this represents an
approximately 1:1 mole ratio of oleic acid binding to alpha-synuclein in the SPA assay.

1.2 Alpha-synuclein point mutants influence the binding of the protein to oleic acids.
Since several lines of evidence from in vitro studies suggest that the N-terminus of alphasynuclein mediates binding to phospholipid vesicles and SDS micelles (Chandra et al., 2003;
Davidson et al., 1998; de Laureto et al., 2006; Eliezer et al., 2001; Ulmer et al., 2005; Varkey et
al., 2013), we asked if the binding of alpha-synuclein to oleic acid is also mediated by the Nterminus of the protein. To address this question, we produced recombinant alpha-synuclein
protein containing familial PD-associated missense mutations that are all located in the Nterminus of the protein, and tested their ability to interact with oleic acid in the SPA assay.
Briefly, each point mutation was created using site-directed mutagenesis. Recombinant alphasynuclein protein containing each mutation was purified as previously described. 0.28µM of
each purified recombinant protein was incubated with his-tagged PVT SPA beads and 3H-labeled
oleic acid at a range of different concentrations for 2 hours at 37°C. The curve was generated for
each mutant by plotting the specific binding versus the range of different concentrations of oleic
acid. Interestingly, we observed either little or no specific binding across the oleic acid
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concentrations tested in the assay for both A30P and E46K mutants (Figure 3b-c), suggesting
that both A30P and E46K mutations disrupt the binding of alpha-synuclein to oleic acid. In
contrast, we observed sigmoidal relationships for A53T, H50Q and G51D mutants, indicating
cooperative binding of each protein to oleic acid that is very similar to WT protein (Figure 3d-f).
To determine Kd, Bmax and Hill coefficient values for each mutant, we analyzed the data with
non-linear regression. We found Kd values of 5.47μM±0.60, 4.35 μM±0.33, 6.19 μM±1.12; Bmax
values of 2409 cpm±488.4, 1553 cpm±94.0, 2619 cpm±941.9; and values of hill coefficient
5.59±2.12, 15.18±7.42, 5.02±2.31; for A53T, G51D and H50Q mutants, respectively. The
binding values of these three mutants are similar to the values of WT-alpha-synuclein (Kd =
4.77μM±0.30, Bmax = 2181cpm±198.5 and hill coefficient = 4.78±1.01), suggesting that
mutations at codon 50, 51 and 53 do not affect the binding interaction of the protein with oleic
acid. Together, these results indicate that binding of alpha-synuclein to oleic acid is also
mediated by the N-terminus of the protein. Specifically, codon 30 and 46 of N-terminus are
required for alpha-synuclein-oleic acid interaction, as evidenced by the absence of binding
observed in both A30P and E46K mutants.
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Figure 3. Alpha-synuclein mutations affect oleic acid binding. Oleic acid binding interactions
with human WT (Figure 3a), A30P (Figure 3b), E46K (Figure 3c), A53T (Figure 3d), G51D
(Figure 3e) and H50Q (Figure 3d) alpha-synuclein were characterized using scintillation
proximity assay (SPA). For both A30P and E46K alpha-synuclein proteins, no significant
binding was observed over the range of oleic acid concentrations tested in the assay (Figure 3bc). The oleic acid binding observed for A53T, G51D and H50Q alpha-synuclein proteins were
similar to that of WT alpha-synuclein (Figure 3a and b-f). Similar Bmax and Kd values were
observed across multiple independent experiments for each protein.
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1.3 Wild type (WT) human alpha-synuclein enhances incorporation of free fatty acid into
phospholipids in HEK293FT cells.
Although Murphy et al did not observe binding of alpha-synuclein to oleic acid using
titration microcalorimetry (Golovko et al., 2005), they observed reduction of fatty acid uptake
and incorporation into phospholipid in alpha-synuclein-KO mice (Golovko et al., 2005; Golovko
et al., 2007). Notably, they also reported that alpha-synuclein affects fatty acid metabolism
through modulation of acyl-CoA synthetases (ACS) enzymatic activity (Golovko et al., 2006).
Thus, it is likely that overexpression of alpha-synuclein may promote ACS enzymatic activity
and fatty acid incorporation rate into phospholipids.
To begin to address this idea, previous studies in Dr. Kotzbauer’s lab explored whether
alpha-synuclein modulates the activity of ACS enzymes in vitro. An in vitro enzymatic assay
was utilized to evaluate the catalytic activity of two isoforms of ACS enzyme (ACSL3 and
ACSL6) in a range of different concentrations of recombinant human WT alpha-synuclein
protein. Interestingly, they found that the catalytic activity of both isoforms increased with a
sigmoidal dose response relationship to the concentration of alpha-synuclein protein (Figure 4a
and b), indicating that the increased enzymatic activity was alpha-synuclein dependent.
Importantly, A30P mutation abolishes the effect of WT alpha-synuclein on catalytic activity of
the enzymes (Figure 4c), whereas the A53T mutation had no significant effect (Figure 4c).
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Figure 4. Over-expression of human WT, but not A30P, alpha-synuclein increases catalytic
activity of Acyl-CoA synthetases (ACS) enzymes. (Unpublished data from Dr. Kotzbauer lab)
The effect of alpha-synuclein on the catalytic activity of two isoforms of ACS enzyme: ACSL3
(Figure 4b and c) and ACSL6 (Figure 4a) were measured in an in vitro enzymatic assay. The
catalytic rates of ACSL6 (Figure 4a) and ACSL3 (Figure 4b) were increased in an alphasynuclein dose dependent manner. A53T alpha-synuclein increased ACSL3 activity similar to
WT alpha-synuclein, whereas A30P alpha-synuclein did not increase ACSL3 activity (Figure
4c).
Based on our finding that the A30P mutation disrupts the binding of alpha-synuclein to
oleic acid, it is possible that the A30P mutation does not promote catalytic activity of ACS
enzyme due to the absence of oleic acid binding. To determine the effect of WT and A30P alphasynuclein on ACS catalytic activity in vivo, we examined fatty acid incorporation rates in
HEK293 cells transfected with alpha-synuclein expression plasmids. Briefly, either human-WT
or human-A30P alpha-synuclein was over-expressed in HEK293FT cells using lipofectamine
mediated transfection. 14C-labeled oleic acid was added to the cell media and incubated with the
cells at 37°C for 15 minutes to allow the cells to metabolize the fatty acid. We then harvested

68

cells, extracted lipids, and separated individual lipid classes using thin layer chromatography
(TLC). To determine the rate of oleic acid incorporation, we compared the amount of 14C-labeled
phosphatidylcholine (PC) in cells over-expressing human WT alpha-synuclein and cells overexpressing human A30P alpha-synuclein to control cells over-expressing no alpha-synuclein.
Notably, we found that over-expressing human WT alpha-syuclein in the cells increased oleic
acid incorporation into PC by approximately 20% (p<0.02 from three independent sets of
experiment) (Figure 5a). In contrast, overexpressing human-A30P alpha-synuclein in the cells
had no effect on the oleic acid incorporation rate (Figure 5b), supporting the idea that oleic acid
binding and ACS enzymatic activity mediate the effect of alpha-synuclein on the fatty
incorporation rate.

Figure 5. Over-expression of human WT, but not A30P, alpha-synuclein increases oleic
acid incorporation into phosphatidylcholine (PC) in HEK293FT cells. Compared to the
control group (vector), HEK293FT cells over-expressing human WT alpha-synuclein exhibited
an average of 20% increase in the rate of oleic acid incorporation into PC (Figure 5a). Oleic acid
incorporation rate into PC was similar between vector and HEK293FT cells over-expressing
A30P alpha-synuclein (Figure 5b). The rate of oleic acid incorporation into PC was presented as
the % difference of control group (vector).
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Because the number of cells and the alpha-synuclein expression level in each sample can
affect the resulting amount of 14C-labeled PC, we estimated cell numbers and alpha-synuclein
expression level using BCA and ELISA, respectively. We observed no difference in cell
numbers (Figure 6a-b) and expression level of alpha-synuclein between WT and A30P groups
(Figure 6c), further indicating that the increase in oleic acid incorporation is mediated by the
binding and enzymatic activity.

Figure 6. Cell numbers and alpha-synuclein expression levels were similar between
HEK293 cells overexpressing Wild-type (WT) or A30P alpha-synuclein. The number of
HEK293FT cells overexpressing human WT (Figure 6a) and A30P (Figure 6b) alpha-synuclein
were estimated using BCA assay. Cell numbers in each group were similar to vector controls.
Protein expression level of alpha-synuclein was determined using ELISA (Figure 6c).
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Discussion
In this study, we demonstrated using a scintillation proximity assay (SPA) that alphasynuclein cooperatively binds monomeric oleic acid with a Kd of 5 μM. Amino acid residues 30
and 46 in the N-terminus of alpha-synuclein protein are required for oleic acid binding, as
evidenced by the observation that both A30P and E46K mutations disrupt binding. We also
demonstrated that alpha-synuclein increases the catalytic rate of Acyl-CoA synthetase (ACS)
enzymes in vitro, and increases the rate of oleic acid incorporation into phosphatidylcholine in
transfected HEK293FT cells. The disruptive effect of the A30P mutation on both fatty acid
binding and enhanced FA incorporation rate indicates that alpha-synuclein promotes conversion
of fatty acids to acyl CoAs by enhanced delivery of fatty acids to acyl CoA synthetase enzymes.
Thus, our results support the hypothesis that alpha-synuclein controls a critical step needed to
utilize fatty acids in multiple metabolic pathways.
SPA is a novel assay to characterize the binding of alpha-synuclein to oleic acid
We are the first to utilize SPA to characterize the binding of alpha-synuclein to fatty acid.
Our results indicate that SPA is a valuable approach to characterize the interaction of alphasynuclein with oleic acid. Because SPA does not require the separation of bound from unbound
ligand, the possibility of losing bound complex due to dissociation or inefficient capture on
filters is reduced. Importantly, the binding we observe using SPA is consistent with previous
studies (Karube et al., 2008; Sharon et al., 2001), confirming a direct interaction between alphasynuclein and oleic acid. The interaction of alpha-synuclein with oleic acid was not observed in
study using titration microcalorimetry (Golovko et al., 2005), possibly because it lacked the
sensitivity to detect an interaction based on thermodynamic measurements. Our results extend
those of Sharon et al by demonstrating cooperativity in binding, in part because we were able to
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detect the specific binding at lower concentration of alpha-synuclein (<0.28µM). However, our
SPA requires further determination of counting efficiency in order to further increase the
accuracy of Bmax calculations. Specifically, the efficiency of his-tagged alpha-synuclein capture
by PVT-SPA beads and the efficiency with which beads capture emissions from 3H-oleic acid
require further characterization.

Characterization of the nature of alpha-synuclein-oleic acid complex
Determination of the critical micelle concentration (CMC) of oleic acid revealed that the
binding we observed in SPA represents the interaction of alpha-synuclein with monomeric oleic
acid. There are two important reasons why we determined CMC of oleic acid. First, although the
CMC of oleic acid has been estimated to be around 6μM (Davis et al., 2011), the CMC can
change depending on the experimental conditions (pH, ionic strength or temperature). Second,
fatty acid, as a surfactant, aggregates to form micelles with different sizes and shapes, which
could exert different effects on its binding partner (Walde, 2006). Therefore, we specifically
determined CMC of oleic acid under the same experimental condition where the binding
interaction was observed. Since we found that the oleic acid concentrations we used in our
binding assay were lower than the estimated CMC of oleic acid (~30uM) in our system, we
concluded that the binding we observed was between alpha-synuclein and monomeric oleic acid.
Our finding of the interaction between alpha-synuclein and monomeric oleic acid has a
physiological significance in brain where the concentration of oleic acid in CSF is approximately
3.6μM (Schmid et al., 2012).

Our observation of an interaction between alpha-synuclein and monomeric oleic acid
could explain the observed effect of alpha-synuclein on fatty acid micelle formation in vitro
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(Broersen et al., 2006; De Franceschi et al., 2009) . Since CMC is determined by solubility of
monomeric fatty acid, the reduction in free fatty acid monomer concentration by formation of
alpha-synuclein-fatty acid complexes is likely to increase CMC. Because the effect of alphasynuclein on CMC of oleic acid has not been determined, we can further determine the ability of
alpha-synuclein to increase CMC of oleic acid. It is also of interest to determine the interaction
of alpha-synuclein with other fatty acid species. It has been previously reported that alphasynuclein affects micellar behavior of polyunsaturated fatty acids (AA and DHA) but not
saturated fatty acids (arachidic and palmitic acids) (Broersen et al., 2006). Brain palmitate
metabolism was decreased in the absence of alpha-synuclein, however, the binding of alphasynuclein to palmitic acid was not detected using titration microcalorimetry (Golovko et al.,
2005). Therefore, we could further characterize the binding of alpha-synuclein to palmitic acids
(saturated fatty acid) and DHA (polyunsaturated fatty acid) using SPA. DHA plays important
roles in brain function. Polyunsaturated fatty acids (PUFAs) can affect membrane properties and
functions when incorporated into phospholipids (Hagve et al., 1998; Hulbert, 2008), PUFAs also
have signaling roles (Bazan et al., 2011; Grintal et al., 2009). One study suggested high binding
affinity of alpha-synuclein toward PUFAs (DHA>AA) using a competition assay in which the
radiolabeled oleic acid binding was measured in the presence of unlabeled PUFA (Sharon et al.,
2001). Direct measurements of binding interactions using 3H-labeled PUFAs would provide
further information on the binding affinities for different fatty acid species. Together, both
binding results and the effect of alpha-synuclein on micellar behavior of fatty acids indicate
direct interactions of alpha-synuclein with several different free fatty acid species.
Importantly, we were also able to relate alpha-synuclein-fatty acid interactions to the
effect of human WT alpha-synuclein on fatty acid metabolism in cells. Our cell culture studies
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revealed that human WT, but not A30P, alpha-synuclein over-expression enhanced the rate of
oleic acid incorporation into phospholipid by approximately 20%. Together with the observation
that the A30P mutation disrupted oleic acid binding, the inability of A30P alpha-synuclein to
promote oleic acid incorporation into phospholipid supports the hypothesis that the regulatory
role of alpha-synuclein in fatty acid metabolism is mediated by the direct binding of alphasynuclein to fatty acids. This idea is further supported by our observations in the in vitro
enzymatic assay that recombinant human WT-alpha-synuclein increases the catalytic activity of
two ACS enzymes, ACSL3 and ACSL6, while recombinant A30P alpha-synuclein has no effect
(unpublished data in Kotzbauer lab). Furthermore, the effect of alpha-synuclein in fatty acid
metabolism observed in our alpha-synuclein over-expression studies are consistent with previous
findings reported in mice with a targeted alpha-synuclein gene mutation, in which fatty acid
incorporation into phospholipid was found to be reduced through reduced enzymatic activity of
acyl-CoA synthetases (Golovko et al., 2005; Golovko et al., 2006; Golovko et al., 2007).
The effect of fatty acid binding on the structural conformation of alpha-synuclein
The N-terminus of alpha-synuclein plays an important role in its interactions with
phospholipid vesicles and SDS micelles and adopts alpha-helical structure upon the bindings
(Chandra et al., 2003; Davidson et al., 1998; de Laureto et al., 2006; Eliezer et al., 2001; Perrin et
al., 2000; Ulmer et al., 2005; Varkey et al., 2013). While studies report alpha-helical structural
change of the protein in the presence of fatty acid (Broersen et al., 2006; Perrin et al., 2001),
whether monomeric fatty acids also induce the conformational changes in the protein is unclear.
Although further studies are needed to determine the changes in alpha-helical contents, our
binding studies using mutagenesis demonstrate that the amino acids at position 30 and 46 in the
N-terminus of protein are required for fatty acid binding. Here, we proposed two possible
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hypotheses of the effect of fatty acid binding on the alpha-synuclein structure based on our
results. First, since monomeric fatty acid is far smaller in size relative to phospholipid vesicles
and micelles, it is possible that fatty acid binding may not be associated with a conformational
change of the protein from unfolded to alpha-helical structure.
Alternatively, similar to binding interactions with phospholipid vesicles (Davidson et al.,
1998; Eliezer et al., 2001) and SDS micelles (de Laureto et al., 2006; Ulmer et al., 2005), alphasynuclein may also adopt alpha-helical structure upon interaction with monomeric fatty acid. The
proline substitution in the A30P mutant disrupts alpha-helix formation (Bussell and Eliezer,
2001) and disrupts binding interactions with vesicles (Bussell and Eliezer, 2004; Perrin et al.,
2000). The E46K mutation also causes local disruption of alpha-helical structure but retains its
ability to interact with phospholipid. Based on the previous reports that both A30P and E46K
mutations reduce the alpha-helical content and our observations in this study that both mutants
disrupted oleic acid binding, we propose that conformational transition to alpha-helical structure
may also be important for oleic acid binding. However, the effect of the E46K mutation on
interactions with fatty acids but not phospholipid vesicles may indicate distinct structural
requirements for fatty acid binding. Further determination of alpha-helical content upon oleic
acid binding using circular dichroism (CD) could provide a better understanding of the role of
alpha-synuclein structural conformation in the interaction with free fatty acids.

Possible roles of fatty acid binding in alpha-synuclein fibril formation
Natively unfolded alpha-synuclein (Weinreb et al., 1996) adopts alpha-helical structure
upon the interaction with phospholipid vesicles (Chandra et al., 2003; Davidson et al., 1998;
Ulmer et al., 2005), but the aggregated form of alpha-synuclein found in neurodegenerative
disorders is defined by beta-sheet structure. Although the normal function of alpha-synuclein is
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not understood, structural changes related to its normal function may affect protein mis-folding
and aggregation. For example, a previous study reported that the conformational transition from
unfolded to alpha-helical structure upon the association of alpha-synuclein with membrane
phospholipid inhibits fibril formation (Zhu and Fink, 2003). The effect of monomeric fatty acid
binding on alpha-synuclein fibril formation has not been studied. While the A30P mutation is
implicated in PD pathogenesis, A30P alpha-synuclein forms fibrils slowly relative to WT alphasynuclein in vitro. The different observations between in vitro and in vivo experimental systems
could be explained by an effect of fatty acids. In the absence of fatty acids in vitro, the rate of
fibril formation depends primarily on the intrinsic ability of the protein to adopt a conformational
change and self-associate. On the other hand, when fatty acids are present in vivo, disruption of
fatty acid binding due to the proline substitution in part could explain the accelerated alphasynuclein pathology in A30P mutant. Alpha-helical structure stabilized by fatty acid binding
could reduce the probability of the protein to adopt β-sheet structure, thereby hindering protein
aggregation. Furthermore, even in the absence of an alpha-helical shift, the formation of alphasynuclein-oleic acid complex could hinder protein aggregation by reducing the ability of free
alpha-synuclein monomers to self –associate, either in the nucleation or extension phases of fibril
formation.

It is also possible that fibril accumulation is regulated by multiple other mechanisms.
Increased intercellular levels of alpha-synuclein monomer may promote fibril formation, as
suggested by alpha-synuclein gene duplication and triplication mutations linked to rare familiar
PD (Singleton et al., 2003). Multiplication of the alpha-synuclein gene is predicted to increase
protein production; thereby increasing the concentration of alpha-synuclein monomers in
neurons. In addition to production, clearance of alpha-synuclein can also regulate the level of
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alpha-synuclein monomers. It has been shown that alpha-synuclein protein is degraded by both
the ubiquitin-proteasome pathways as well as lysosome pathways (Lee et al., 2004; Mak et al.,
2010) and therefore alteration in alpha-synuclein clearance may also contribute to fibril
formation.

Potential role of fatty acid metabolism in the pathogenesis of PD
Our findings in this study support the regulatory role of alpha-synuclein in fatty acid
metabolism. Our findings further suggest that altered fatty acid metabolism may also be
implicated in PD pathogenesis. In fact, a population-based Rotterdam study looked at the
relationship between dietary intake of fatty acids and the risk of developing PD. The study
reported that increased dietary intake of total fat, monounsaturated fatty acids and
polyunsaturated fatty acids lowered the risk of developing PD (de Lau et al., 2005), suggesting
that altered fatty acid metabolism could contribute to the pathogenesis of PD. Furthermore,
altered fatty acid metabolism is also associated with a genetic mutation that increases the risk of
developing PD. The glucocerebrosidase (GBA) gene encodes the enzyme β-glucocerebrosidase,
which hydrolyzes glucosylceramide to produce ceramide. While homozygous mutation of GBA
gene causes an autosomal recessive lysosomal storage disorder called Gaucher’s disease,
heterozygous GBA mutations are associated with an increased risk of PD (Mitsui et al., 2009;
Sidransky and Lopez, 2012). What causes the increased susceptibility to PD in patients with
heterozygous GBA mutations remains unclear. One study compared fatty acid levels in CSF of
GBA-PD patients with both idiopathic PD and healthy controls, and found significantly lower
fatty acid levels in CSF of GBA-PD patients (Schmid et al., 2012), further supporting the
correlation of altered fatty acid metabolism with increased risk of PD. Hydrolysis of
glucosylceramide is an important intermediate step in sphingolipid metabolism in which
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sphingolipid is broken down to produce free fatty acids and sphingosine. Although
glucosylceramidase is not directly involved in the hydrolysis reaction that produces free fatty
acids, it certainly could be the rate limiting step in the conversion of glucosylceramide to fatty
acids. Therefore, reduced enzymatic activity of glucosylceramidase caused by GBA mutations
could change the rate of free fatty acid production.

The potential involvement of fatty acid metabolism in the pathogenesis of PD raises the
importance of studying dietary fatty acid intake and fatty acid levels in CSF in PD patients.
Future studies that relate changes in fatty acid levels and changes in alpha-synuclein levels in
CSF could further confirm the interaction of alpha-synuclein and fatty acids in brain and the
implication of alpha-synuclein-fatty acid interaction in the pathogenesis of PD.

Implication of alpha-synuclein-fatty acid interaction in pla2g6-KO mice
The underlying molecular mechanism of how PLA2G6 mutation causes
neurodegeneration remains to be defined. Since the conversion of free fatty acid to acyl-CoA is
an essential step that regulates downstream metabolic processes, deficiency in free fatty acid
production caused by PLA2G6 mutations is considered as one of the possible mechanisms
underlying neurodegeneration. Our results support the role of alpha-synuclein in the fatty acid
activation step. Specifically, alpha-synuclein directly binds to free fatty acids and increases the
enzymatic activity of acyl-CoA synthetase, resulting in increased acyl-CoA production. PLA2G6
mutations cause the disruption of Pla2g6 enzyme to produce free fatty acid through the
hydrolysis of phospholipid. Although free fatty acids are available from other sources, such as
dietary intake and breakdown by other lipases, the free fatty acid pools that are available for
conversion to acyl-CoA are likely to be significantly reduced in INAD. Based on our findings of
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the role of alpha-synuclein in the fatty acid activation step, we hypothesize that the alphasynuclein mediated increase in acyl-CoA production could compensate for the deficiency in free
fatty acid production in Pla2g6-KO mice. Therefore, the ability of alpha-synuclein to increase
acyl-CoA production could explain why over-expression of human WT alpha-synuclein
improves the neurologic impairment of Pla2g6-KO mice.

Potential role of tetrameric structure in the interaction of alpha-synuclein with fatty acids
The observation of cooperativity in binding is of special interest in the current debate
about the structure of native alpha-synuclein. Although it remains controversial, studies have
indicated that native alpha-synuclein exists as a tetramer with alpha-helical structure rather than
a natively unfolded monomer (Bartels et al., 2011; Wang et al., 2011). In this study, to
understand the cooperativity and the nature of alpha-synuclein-oleic acid complex observed in
SPA, we estimated the mole ratio of alpha-synuclein to oleic acid to be approximately 1:1.
Cooperative binding indicates that binding of a ligand to one binding site on a receptor increases
the binding affinity of the ligand to other sites on the same receptor. If the 1:1 ratio is correct, it
indicates that alpha-synuclein must exist as a multimer in order to produce cooperative binding,
and at least four alpha-synuclein monomers must be present in the complex in order to explain
the hill coefficient of 4 observed in our assays. Alternatively it is possible that we underestimated
the Bmax value for oleic acid in the assay, possible because we over-estimated the efficiency of
dpm detection in the assay, in which case it is possible that 4 or more oleic acid molecules bind
to a single alpha-synuclein monomer in a cooperative fashion. We estimated the molecular
weight of recombinant alpha-synuclein to be 57kD using static light scattering (SLS) which is
consistent with the size reported for both the disordered monomer as well as the alpha-helical
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tetramer. Further size measurements in the presence of fatty acid, perhaps in combination with
circular dichroism studies to measure alpha-helical content, could help determine structural
changes that occur when alpha-synuclein binds to fatty acids.
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Future Directions
In our study, we demonstrated the binding interaction of alpha-synuclein with oleic acid
using SPA assay. Although oleic acid is a common monounsaturated fatty acid, it is only one
type of many fatty acids that exist. Structurally different fatty acids (ex, saturated vs unsaturated)
play different roles in lipid metabolism. Previous studies suggest that alpha-synuclein interacts
with polyunsaturated fatty acid (ex. DHA, AA) but not with saturated fatty acids (ex. Palmitic
acid) although affinities were not measured or compared (Broersen et al., 2006). To further
understand the interaction of alpha-synuclein with fatty acids, we propose to evaluate the binding
of alpha-synuclein to other fatty acids species using the same method we used for oleic acid. If
the binding is observed, we can examine binding affinities (Kd value) of alpha-synuclein toward
different fatty acids in our SPA assay. Since each fatty acid may be involved in different
metabolic pathways, differences in binding affinity will be helpful to understand the potential
role of alpha-synuclein in these particular metabolic pathways.
Our results from in vitro and cell culture studies support the regulatory role of alphasynuclein in fatty acid metabolism by increasing acyl-CoA production. To further determine if
alpha-synuclein increases Acyl-CoA levels in vivo, we propose to study the effect of alphasynuclein over-expression on fatty acid incorporation in mice. Using the in vivo kinetic method
described by others (Golovko et al., 2006; Rapoport, 2001), we can measure the kinetics of brain
oleic acid metabolism in WT alpha-synuclein transgenic mouse line (M7 syn) in which human
WT alpha-synuclein is over-expressed in neurons (Giasson et al., 2002). Based on the results in
this study, we expect to detect a higher rate of oleic acid incorporation into phospholipids in M7
syn transgenic mice, compared to wild-type mice. Such observations will further support our
findings in this study. In addition, our results suggested that the fatty acid binding is required for
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alpha-synuclein to regulate fatty acid metabolism. To further examine the effect of binding
interaction on the ability of alpha-synuclein to promote acyl-CoA synthesis, we propose to
compare the kinetics of brain oleic acid metabolism in wild-type mice to that in wild-type mice
over-expressing either the A30P or E46K mutation.
Based on the ability of alpha-synuclein to increase acyl-CoA production, we predicted
that an alpha-synuclein-mediated increase in acyl-CoA synthesis compensates the deficiency in
free fatty acid production caused by PLA2G6 mutation in Pla2g6-KO mice. To further test if our
prediction underlies the protective effect of human WT alpha-synuclein over-expression on the
motor performance observed in Pla2g6-KO mice, we propose to measure the kinetics of brain
oleic acid metabolism in Pla2g6-KO/human WT alpha-syn transgenic (Pla2g6-/-syn+/+) mice
and appropriate controls; Pla2g6-KO/human WT alpha-syn non-transgenic (Pla2g6-/-syn-/-),
Pla2g6-WT/human WT alpha-syn transgenic (Pla2g6+/+syn+/-) and WT (Pla2g6+/+syn-/-) mice,
using the same in vivo kinetic method described previously (Golovko et al., 2006; Rapoport,
2001). If we detect a higher rate of oleic acid incorporation into phospholipid in Pla2g6KO/human WT alpha-syn transgenic (Pla2g6-/-syn+/+) mice compared to Pla2g6-KO/human
WT alpha-syn non-transgenic (Pla2g6-/-syn-/-), this observation will confirm our prediction that
the protective effect of alpha-synuclein on motor performance is mediated by increased acylCoA synthesis which compensates for impaired free fatty acid production caused by PLA2G6
mutations.
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Currently, no cure is available for INAD. Based on our knowledge about the possible role
of fatty acid metabolism in pathogenesis of the disease and findings in our current study, further
studies can be proposed to test potential therapeutic approaches that target the fatty acid
activation pathway in INAD. For instance, if our hypothesis that an alpha-synuclein-mediated
increase in acyl-CoA synthesis underlies the observed improvement in motor performance of
Pla2g6-KO/human WT alpha-synuclein transgenic mice is confirmed, such observations will
support acyl-CoA synthesis as a therapeutic target for treating INAD. While the ability of alphasynuclein to promote acyl-CoA production is supported by our studies and others (Golovko et al.,
2005; Golovko et al., 2006), increasing the expression level of alpha-synuclein in INAD
patients is impractical approach due to the self-aggregation property of the protein. Instead, it is
appropriate to target ACS enzymes. Therefore, identifying and developing drugs that increase the
protein expression level of ACS enzymes or that increase enzymatic activity could increase acylCoA production in INAD patients.
Retinoid X receptor (RXR) is a ligand-dependent nuclear receptor transcription factor
that can interact with other transcriptional activators (ex. liver X receptor and peroxisome
proliferator-activated receptor) to increase the expression of enzymes that regulate cholesterol
and fatty acid metabolism (Martin et al., 2000; Yoshikawa et al., 2001). Sterol response element
binding protein (SREBP-1c) is a transcription regulator that binds to sterol regulatory elements
of genes that encode enzymes for fatty acid synthesis; thereby up-regulation of SREBP-1c
expression increases the expression level of fatty acid synthetases that produce acyl CoAs
(Martin et al., 2000). For example, Bexarotene, a FDA approved RXR agonist, increases ACSL3
mRNA levels. Brain ACSL3 mRNA level was increased by 41% in mice treated with
Bexarotene diet compared to mice with control diet (Bagchi and Kotzbauer, unpublished results).
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Interestingly, one study also reported that nicotine increases mRNA and protein level of ACSL6
in mouse brain (Chen et al., 2011). Further studies could test whether these approaches to
increase brain acyl CoA levels reduce neurologic impairment in Pla2g6-KO mice.
A better understanding of therapeutic targets is helpful for probing the molecular
mechanisms of drug actions and for identifying features that guide new drug design. Therefore, a
better understanding of brain ACS enzymes is helpful in developing approaches to increase
activities of these enzymes. ACS enzymes play a critical role in fatty acid metabolism. Except
for eicosanoid metabolism, esterification of free fatty acid by ACS enzymes to acyl-CoA is
required for fatty acids to be utilized in downstream metabolic processes. In addition to their
enzymatic functions to activate free fatty acids, they also regulate cellular uptake and channeling
of fatty acids (Mashek et al., 2007). ACS enzymes are grouped into families depending on the
acyl-chain lengths of free fatty acids to which they interact (Soupene and Kuypers, 2008).
Isoforms in each ACS family differ in their substrate preferences and intracellular localization
(Lewin et al., 2001; Mashek et al., 2007; Soupene and Kuypers, 2008), suggesting the activity of
each enzyme to regulate fatty acid metabolism in a localization-dependent manner. Of the eleven
enzymes from the three gene families; long-chain acyl-CoA synthetases (ACSLs), Bubblegum
acyl-CoA synthetases (ACSBG) and Fatty acid transporter protein (FATPs), ACSL3, ACSL6,
FATP4 and ACSBG1 are highly expressed in the brain (Chen et al., 2011; Golovko et al., 2006;
Hall et al., 2005; Kee et al., 2003; Pei et al., 2003). However, the physiologic function and
localization of each enzyme within the brain have not been completely characterized. Since the
direct protein-protein interaction was not detected between alpha-synuclein and two isoforms
(ACSL3 and ACSL6) of ACS enzymes using co-immunoprecipitation (data not shown), we
hypothesized based on our results that alpha-synuclein binds to fatty acid and then delivers fatty
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acid to the enzyme sites for increased fatty acid activation. Further studies that examine the
localization patterns of ACS in neurons can test our hypothesis. The observation of ACS
enzymes in dendrites, axons and presynaptic terminals where alpha-synuclein and pla2g6 are
localized will further support our hypothesis.
The results of our binding studies also have potential implications in the pathogenesis of
PD. We speculate that the interaction of alpha-synuclein with fatty acids could reduce the
probability of the protein to self-aggregate, because of either the conformational changes to more
stable structure or the reduction of free monomer concentration. Using an in vitro fibril
formation assay, we can determine the effect of fatty acid on the rate of fibril formation for WT,
A30P, and E46K alpha-synuclein protein. An observed reduction in the fibril formation rate for
WT but not for A30P and E46K in the presence of fatty acid could support the notion that fatty
acid binding affects self-aggregation. Cell-based assays and transgenic mice have been
developed to study fibril formation by alpha-synuclein protein. To further study the relationship
between fatty acids and fibril formation, we could add fatty acid to a cell-based aggregation
assay and examine changes in the rate of fibril formation. We also could modulate the level of
fatty acids in the diet for transgenic mice and evaluate corresponding changes in the
accumulation of fibrillar alpha-synuclein.
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